The ability to transport and concentrate iodide, a fundamental property of normally functioning thyroid epithelial cells, represents a key step in the production of the iodine-containing thyroid hormones. Iodide uptake across the basolateral membrane of thyroid follicular cells is made possible by the Na þ /I ¹ symporter (NIS), an active co-transport mechanism that is driven by an inwardly directed Na þ gradient. In addition to providing a mechanism for several diagnostically useful tests such as the thyroidal radioiodine uptake test and the perchlorate discharge test, NIS-mediated active I ¹ -accumulation by thyroid tissue is a crucial requirement for the success of radioactive iodine therapy.
As highlighted earlier (1), cloning of the rat NIS from an FRTL-5 cell-derived cDNA library by Carrasco's group has revealed an open reading frame of 1854 nucleotides that encodes a 618 amino acid intrinsic membrane protein with 12 putative membrane-spanning domains. This discovery has set the stage for Smanik et al. (2) , who subsequently cloned the human homologue of NIS from a human thyroid cDNA library. An open reading frame (nucleotides 348-2276) of human NIS (hNIS) encodes a protein of 643 amino acids that shares 84% amino acid identity with recombinant NIS (rNIS) and has a predicted molecular mass of 68·7 kDa. Assignment of the 12 transmembrane domains in hNIS has been based on the proposed transmembrane domains of the rNIS, in which the two protein sequences are highly conserved. Transient transfection of COS-7 cells with the hNIS cDNA clone resulted in perchlorate-sensitive iodide uptake, confirming expression of functionally intact hNIS. Using reverse transcriptase-polymerase chain reaction, the authors detected hNIS expression at variable levels in papillary thyroid carcinoma tissues, but not in any of the thyroid carcinoma cell lines that lack iodide uptake activity, suggesting that loss of iodide-concentrating activity in thyroid carcinomas may be due to a loss of hNIS expression.
Shortly after cloning of hNIS, Kosugi et al. (3) succeeded in establishing stable expression of recombinant rNIS in a Chinese hamster ovary (CHO) cell line. Subsequent analysis of its basic biochemical and electrophysiological properties, including time course, Na þ -dependency, kinetics and competitive inhibition by perchlorate and thiocynate, revealed characteristics very similar to those of rNIS in FRTL-5 cells. Thus availability of CHO cells stably expressing NIS provides a novel tool, not only for sensitive analysis of iodide uptake, but for detection of hNIS-directed antibodies in sera of patients with autoimmune thyroid disorders.
Presence of such antibodies had first been suspected by Raspe et al. (4) , who noted inhibition of chronic TSH-induced iodide uptake by cultured dog thyrocytes when exposed to serum of a patient with Hashimoto's thyroiditis, autoimmune gastritis and rheumatoid arthritis. This early observation has recently gained support from Endo et al. (5), who examined a limited number of sera from patients with Graves' disease and Hashimoto's thyroiditis for the presence of NIS antibodies. Using Western blotting with recombinant full-length rNIS and a rabbit antibody raised against the N-terminal portion of an NIS fusion protein, Endo's group were able to detect 80 kDa rNIS immunoreactivity in 22 of 26 sera (84%) derived from patients with Graves' disease and in three of 20 sera (15%) from patients with Hashimoto's thyroiditis. Of note, rNIS immunoreactivity in patients' sera was not correlated with TSH-binding inhibiting immunoglobulin (TBII) activity, thyroid-stimulating antibody (TSAb) activity, and titres of thyroglobulin or thyroid peroxidase antibodies, suggesting that the immune response against NIS may represent an independent, yet unrecognized phenomenon in autoimmune thyroid disease.
In addition to serving as markers of the underlying autoimmune process, NIS-directed antibodies may affect iodide uptake by the thyroid gland, thereby influencing thyroid function in patients with autoimmune thyroid disease. As reported in another paper by Endo et al. (6), I
¹ transport inhibitory activity indeed appears to be present in IgG derived from some patients with Hashimoto's thyroiditis. Four of 34 sera obtained from patients with Hashimoto's thyroiditis showed strong reactivity with recombinant rNIS by Western blot analysis. When tested in CHO-K1 cells stably expressing rNIS, IgG prepared from these four patients were capable of inhibiting iodide uptake activity by 14-62%. Interestingly, protein A affinity chromatography was required for purification of IgG, because several patients' and normal sera were noted to contain dialysable inhibitors of NIS activity. Moreover, the two IgGs with strongest I ¹ transport inhibitory activity were found to bind to a synthetic peptide corresponding to the 6th extracellular loop of rNIS. These exciting data suggest that some NIS antibodies may indeed act to modulate thyroid function in patients with Hashimoto's thyroiditis and, thus, may have a role in the hypothyroidism of some patients with autoimmune thyroid disease.
Taking the theme a step further, Morris et al. (7) have recently used a carefully calibrated ELISA system to examine IgG prepared from sera of patients with autoimmune thyroid disease for their binding to rNIS peptides. For this purpose, the authors used automated chemistry, HPLC purification and mass spectroscopy to generate synthetically a series of 21 well-characterized rNIS peptides that replicate the entire sequence of the 13 extramembranous domains of rNIS. IgG were protein A affinity-purified from sera of 27 patients with Graves' disease, 27 patients with Hashimoto's thyroiditis and 20 healthy controls. Binding of patients' IgG significantly greater than normal IgG was observed to six peptides representing the extramembranous domains 8, 11, 12 and 13 of rNIS. Most notably, peptide 262-280 (extramembranous domain 8) and peptides 468-487 and 498-517 (both extramembranous domain 12) were recognized by 44%, 59% and 63% of Graves' IgG and by 15%, 11% and 26% of Hashimoto's IgG respectively, but not by any of the control IgG.
There is thus now mounting evidence to conclude that sera of patients with autoimmune thyroid diseases, in particular Graves' disease, contain antibodies that cross-react with rNIS, and that several of the extramembranous domains constitute major antigenic epitopes. Thus, if confirmed by studies using human NIS peptides or even whole protein, the list of established thyroid autoantigens (thyroid peroxidase, thyroglobulin, thyrotrophin receptor) will soon have to include the NIS as its latest, but perhaps not least important, member.
